EMJ Oncology 8 [Supplement 3] . 2020

Journal Info

Patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) derive little benefit from standard therapies and have an extremely poor prognosis. Recent data has demonstrated that adding an anti-epidermal growth factor receptor (EGFR) agent to a BRAF inhibitor, with or without an MEK inhibitor, improves overall survival and response rates compared to irinotecan-based chemotherapy for these patients.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?